Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 4.13B | 2.2% |
| Gross Profit | 2.9B | 1.6% |
| Cost of Revenue | 3.09B | 3.8% |
| Operating expense | 2.16B | 7.1% |
| Net Income | 468M | 44.4% |
| EBITDA | 952M | 33.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 38.1B | 2.6% |
| Total Liabilities | 17.4B | 3.8% |
| Total Equity | 20.7B | 1.7% |
| Shares Outstanding | 1.47B | 0.1% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 1B | 23.2% |
| Cash from investing | -1.43B | 426.6% |
| Cash from financing | 7M | 70.8% |
EPS
Financial Highlights for Boston Scientific in Q3 '24
Boston Scientific reported a revenue of 4.13B, which is a 2.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.9B, marking a 1.6% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 3.09B, a -3.8% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 2.16B, showing a -7.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 468M, showing a 44.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 952M, showing a 33.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Boston Scientific with growth in revenue, gross profit, and net income.
